TY - JOUR
T1 - The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation
AU - Brindley, David A
AU - French, Anna
AU - Suh, Jane
AU - Roberts, MacKenna
AU - Davies, Benjamin
AU - Pinedo-Villanueva, Rafael
AU - Wartolowska, Karolina
AU - Rooke, Kelly
AU - Kramm, Anneke
AU - Judge, Andrew
AU - Morrey, Mark
AU - Chandra, Amit
AU - Hurley, Hannah
AU - Grover, Liam
AU - Bingham, Ian
AU - Siegel, Bernard
AU - Rattley, Matt S
AU - Buckler, R Lee
AU - McKeon, David
AU - Krumholz, Katie
AU - Hook, Lilian
AU - May, Michael
AU - Rikabi, Sarah
AU - Pigott, Rosie
AU - Morys, Megan
AU - Sabokbar, Afsie
AU - Titus, Emily
AU - Laabi, Yacine
AU - Lemaitre, Gilles
AU - Zahkia, Raymond
AU - Sipp, Doug
AU - Horne, Robert
AU - Bravery, Christopher
AU - Williams, David
AU - Wall, Ivan
AU - Snyder, Evan Y
AU - Karp, Jeffrey M
AU - Barker, Richard W
AU - Bure, Kim
AU - Carr, Andrew J
AU - Reeve, Brock
PY - 2013/12
Y1 - 2013/12
N2 - Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
AB - Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
KW - Cell- and Tissue-Based Therapy
KW - Humans
KW - Intellectual Property
KW - Pluripotent Stem Cells
KW - Stem Cell Research/legislation & jurisprudence
KW - Translational Medical Research/legislation & jurisprudence
UR - https://www.liebertpub.com/doi/10.1089/scd.2013.0403
U2 - 10.1089/scd.2013.0403
DO - 10.1089/scd.2013.0403
M3 - Article
C2 - 24304079
SN - 1547-3287
VL - 22
SP - 63
EP - 72
JO - Stem cells and development
JF - Stem cells and development
IS - Suppl 1
ER -